Conv. Plasma
Nigella Sativa

All HCQ studies
Meta analysis
study COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Symp. case 82% Improvement Relative Risk Symp. case (b) 88% Case 29% HCQ for COVID-19  Raabe et al.  Prophylaxis Is pre-exposure prophylaxis with HCQ beneficial for COVID-19? Prospective study of 130 patients in the USA Fewer symptomatic cases with HCQ (not stat. sig., p=0.17) Raabe et al., medRxiv, July 2022 Favors HCQ Favors control

Hydroxychloroquine pre-exposure prophylaxis to prevent SARS-CoV-2 among health care workers at risk for SARS-CoV-2 exposure: A nonrandomized controlled trial

Jul 2022  
  Source   PDF   All   Meta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
*, now known with p < 0.00000000001 from 421 studies, recognized in 42 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,800+ studies for 60+ treatments.
Small prophylaxis study with 130 healthcare workers in the USA, showing lower symptomatic cases with HCQ prophylaxis, without statistical significance. HCQ participants were significantly older. The only symptomatic HCQ patient reported headache only as a potential COVID-19 symptom.
risk of symptomatic case, 82.2% lower, RR 0.18, p = 0.17, treatment 1 of 59 (1.7%), control 2 of 21 (9.5%), NNT 13.
risk of symptomatic case, 88.4% lower, RR 0.12, p = 0.07, treatment 0 of 59 (0.0%), control 2 of 21 (9.5%), NNT 10, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), fever.
risk of case, 28.8% lower, RR 0.71, p = 0.65, treatment 4 of 59 (6.8%), control 2 of 21 (9.5%), NNT 36, seroconversion.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Raabe et al., 3 Jul 2022, prospective, USA, preprint, 7 authors, trial NCT04354870 (history). Contact:
This PaperHCQAll
Hydroxychloroquine pre-exposure prophylaxis to prevent SARS-CoV-2 among health care workers at risk for SARS-CoV-2 exposure: A nonrandomized controlled trial
MD Vanessa N Raabe, MD Andrew Fleming, Ph. D Marie I Samanovic, MD Lilin Lai, Ph. D Hayley M Belli, MD Mark J Mulligan, H Michael Belmont
Background: Aerosol-generating procedures increase the risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among health care workers (HCWs). An effective pre-exposure prophylaxis would mitigate this risk. Objective: To determine the efficacy of pre-exposure prophylactic hydroxychloroquine for the prevention of SARS-CoV-2 infection and symptomatic coronavirus 19 disease (COVID-19) among HCWs at high occupational risk of SARS-CoV-2 exposure. Methods: 130 HCWs in the New York University Langone Health System (NYULHS) who performed aerosol-generating procedures on patients with COVID-19 or provided bedside care for inpatients with COVID-19 or persons with suspected COVID-19 in an emergency department, for at least three shifts in a 7-day period, during the first 2020 COVID-19 wave in New York City were enrolled. Participants elected to take oral hydroxychloroquine, 600 mg on day 1 followed by 200 mg daily, or not take hydroxychloroquine for up to 90 days. Participants self-collected dried blood spots and completed digital questionnaires regarding COVID-19 symptoms, adverse events, and other COVID-19 medication use. Results: Six participants (7.5%) seroconverted during the trial: four who took hydroxychloroquine (6.8%) and two who declined hydroxychloroquine (9.5%). All participants not taking hydroxychloroquine reported COVID-19 symptoms at seroconversion compared to one of four participants (25%) who took hydroxychloroquine. Adverse events occurred in eight participants (9.6%) on hydroxychloroquine and were mostly mild. .
Conflicts of Interest Data Sharing Statement Individual level data from participants will not be shared to protect the privacy of the participating health care workers. . Serious Adverse Events 0 (0) (0) Grade II 0 (0) (0) Grade II 0 (0) (0) Grade II 0 (0) (0) Grade III 0 (0) (0) Serious Adverse Events 0 (0) (0) 440 441 .
Abella, Jolkovsky, Biney, Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis Among Health Care Workers: A Randomized Clinical Trial, JAMA Intern Med
Brown, Peltan, Kumar, Hydroxychloroquine vs. Azithromycin for Hospitalized Patients with COVID-19 (HAHPS): Results of a Randomized, Active Comparator Trial, Ann Am Thorac Soc
Family, None
Fantini, Scala, Chahinian, Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection, Int J Antimicrob Agents
Geleris, Sun, Platt, Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19, N Engl J Med
Grau-Pujol, Camprubí-Ferrer, Marti-Soler, Pre-exposure prophylaxis with hydroxychloroquine for COVID-19: a double-blind, placebo-controlled randomized clinical trial, Trials
Hill, COVID-19 Cases and Deaths by Race/Ethnicity: Current Data and Changes Over Time
Ip, Berry, Hansen, Hydroxychloroquine and tocilizumab therapy in COVID-19 patients-An observational study, PLoS One
Jung, Kim, Kim, Effect of hydroxychloroquine pre-exposure on infection with SARS-CoV-2 in rheumatic disease patients: a population-based cohort study, Clin Microbiol Infect
Liu, Cao, Xu, Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro, Cell Discov
Lucchesi, Silimbani, Musuraca, Clinical and biological data on the use of hydroxychloroquine against SARS-CoV-2 could support the role of the NLRP3 inflammasome in the pathogenesis of respiratory disease, J Med Virol
Macías, González-Moreno, Sánchez-García, Similar incidence of coronavirus disease 2019 (COVID-19) in patients with rheumatic diseases with and without hydroxychloroquine therapy, PLoS One
Magagnoli, Narendran, Pereira, Outcomes of Hydroxychloroquine Usage in United States Veterans Hospitalized with COVID-19, Med (
Mahévas, Tran, Roumier, Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data, Bmj
Rajasingham, Bangdiwala, Nicol, Hydroxychloroquine as Pre-exposure Prophylaxis for Coronavirus Disease 2019 (COVID-19) in Healthcare Workers: A Randomized Trial, Clin Infect Dis
Richard, Kampo, Hechavarria, Elucidating the Pivotal Immunomodulatory and Anti-Inflammatory Potentials of Chloroquine and Hydroxychloroquine, J Immunol Res
Rosenberg, Dufort, Udo, Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State, Jama
Sands, Wenzel, Mclean, No clinical benefit in mortality associated with hydroxychloroquine treatment in patients with COVID-19, Int J Infect Dis
Schwartz, Boesen, Cerchiaro, Assessing the efficacy and safety of hydroxychloroquine as outpatient treatment of COVID-19: a randomized controlled trial, CMAJ Open
Self, Semler, Leither, Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19: A Randomized Clinical Trial, Jama
Sivapalan, Ulrik, Lapperre, Azithromycin and hydroxychloroquine in hospitalised patients with confirmed COVID-19-a randomised double-blinded placebo-controlled trial, Eur Respir J
Sjöwall, Azharuddin, Frodlund, SARS-CoV-2 Antibody Isotypes in Systemic Lupus Erythematosus Patients Prior to Vaccination: Associations With Disease Activity, Antinuclear Antibodies, and Immunomodulatory Drugs During the First Year of the Pandemic, Front Immunol
Stadlbauer, Tan, Jiang, Repeated cross-sectional sero-monitoring of SARS-CoV-2 in New York City, Nature
Stokes, Zambrano, Anderson, Coronavirus disease 2019case surveillance -United States, January 22, MMWR Morb Mortal Wkly Rep
Ulrich, Troxel, Carmody, Treating COVID-19 With Hydroxychloroquine (TEACH): A Multicenter, Double-Blind Randomized Controlled Trial in Hospitalized Patients, Open Forum Infect Dis
Vincent, Bergeron, Benjannet, Chloroquine is a potent inhibitor of SARS coronavirus infection and spread, Virol J
Vitte, Michel, Mezouar, Immune Modulation as a Therapeutic Option During the SARS-CoV-2 Outbreak: The Case for Antimalarial Aminoquinolines, Front Immunol
Yao, Ye, Zhang, In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Clin Infect Dis
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop